MediBeacon Transdermal GFR Measurement System (TGFR)
Medibeacon, Inc. · Decision date Jan 17, 2025
What did the FDA approve?
FDA records P230019 as an original PMA application. The recorded decision is approval, dated Jan 17, 2025.
FDA approval order statement
Approval for the MediBeacon Transdermal GFR System (TGFR) intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time. This device has been validated in patients with stable renal function.The MediBeacon TGFR is not approved for use in patients with GFR <15 ml/min/1.73 m2, GFR >120 ml/min/1.73m2, patients on dialysis, or anuric patients. The use of this device in patients with dynamic and rapidly changing renal function has not been validated. This device is not intended to diagnose acute kidney injury (AKI).The MediBeacon TGFR Sensor and exogenous tracer agent, Lumitrace injection, are single use and are only used with the MediBeacon TGFR. The MediBeacon TGFR Sensor is a single use device intended to attach to the patient's skin and excite fluorescence in Lumitrace injection, the tracer agent, and measure the returning light intensity. The data is sent to the MediBeacon TGFR Monitor. Lumitrace is an injectable exogenous fluorescent tracer indicated for use with the MediBeacon Transdermal GFR System (TGFR) for Glomerular Filtration Rate assessment.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jan 17, 2025
Regulatory record facts
- Identifier
- P230019
- Regulatory pathway
- Premarket approval application
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- Decision code
- APPR
- Decision date
- Jan 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230019 received
Application receipt date recorded by FDA.
P230019 · FDA decision
APPR
P230019/S005 · Related supplement
MediBeacon Transdermal GFR System
Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MediBeacon Transdermal GFR SystemP230019/S005 | Medibeacon, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medibeacon, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141
Sources and methodology
- Original FDA record: P230019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records